Resveratrol attenuates inflammatory hyperalgesia by inhibiting glial activation in mice spinal cords

Molecular Medicine Reports

Volumn 13, Issue 5, 2016, Pages 4051-4057

  Wang, Lin Lin ^a,b   Shi, Dong Ling ^a,b   Gu, Hui Yao ^c   Zheng, Ming Zhi ^c   Hu, Jue ^c   Song, Xing Hui ^c   Shen, Yue Liang ^c   Chen, Ying Ying ^c  

^a Department of Physiology ^*  (China)

^b Center for Stem Cell and Tissue Engineering   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glial activation; Inflammation; Lipopolysaccharide; Pain; Sirtuin 1

Indexed keywords

ACETIC ACID; ADAPTOR PROTEIN; ENZYME INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; EX 257; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; RESVERATROL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; LIPOPOLYSACCHARIDE; STILBENE DERIVATIVE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; GLIA CELL; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY PAIN; LATENT PERIOD; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; SPINAL CORD; SPINAL CORD DORSAL HORN; TAIL FLICK TEST; WESTERN BLOTTING; WRITHING TEST; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; GLIA; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; NEUROGLIA; SPINAL CORD; STILBENES;

EID: 84964702288     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5027     Document Type: Article

References (53)

1. Watkins LR and Maier SF: Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med 257:139-155, 2005.
2. Schinkel C, Gaertner A, Zaspel J, Zedier S, Faist E and Schuermann M: Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 22:235-239, 2006.
3. Koch A, Zacharowski K, Boehm O, Stevens M, Lipfert P, von Giesen HJ, Wolf A and Freynhagen R: Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res 56:32-37, 2007.
4. Jiang YH, Peng CH, Liu HT and Kuo HC: Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One 8:e76779, 2013.
5. Sandhir R, Gregory E, He YY and Berman NE: Upregulation of inflammatory mediators in a model of chronic pain after spinal cord injury. Neurochem Res 36:856-862, 2011.
6. Laird BJ, McMillan DC, Fayers P, Fearon K, Kaasa S, Fallon MT and Klepstad P: The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 18:1050-1055, 2013.
7. Sun AY, Wang Q, Simonyi A and Sun GY: Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 41:375-383, 2010.
8. Pangeni R, Sahni JK, Ali J, Sharma S and Baboota S: Resveratrol: Review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 11:1285-1298, 2014.
9. Cheng W, Zhao Y, Liu H, Fan Q, Lu FF, Li J, Yin Q and Yan CD: Resveratrol attenuates bone cancer pain through the inhibition of spinal glial activation and CX3CR1 upregulation. Fundam Clin Pharmacol 28:661-670, 2014.
10. Sharma S, Kulkarni SK and Chopra K: Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Fundam Clin Pharmacol 21:89-94, 2007.
11. Falchi M, Bertelli A, Galazzo R, Viganö P and Dib B: Central antalgic activity of resveratrol. Arch Ital Biol 148:389-396, 2010.
12. Svajger U and Jeras M: Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol 31:202-222, 2012.
13. Institute of Laboratory Animal Resources (US). Committee on Care, Use of Laboratory Animals, and National Institutes of Health (US). Division of Research Resources: Guide for the care and use of laboratory animals. 8th edition. National Academies Press, Washington, DC, 2011.
14. Zhao H, Luo F, Li H, Zhang L, Yi Y and Wan J: Antinociceptive effect of tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKβ phosphorylation and the COX-2/PGE2 pathway in mice. PLoS One 9:e94586, 2014.
15. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL and Uhl GR: Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549, 1997.
16. Clark MR: Targeting systemic inflammation in patients with obesity-related pain: How best to prevent acute pain from becoming chronic? J Fam Pract 62(9 Suppl CHPP):S3-S9, 2013.
17. Ribeiro RA, Vale ML, Thomazzi SM, Paschoalato AB, Poole S, Ferreira SH and CunhaFQ: Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 387:111-118, 2000.
18. Jha MK, Seo M, Kim JH, Kim BG, Cho JY and Suk K: The secretome signature of reactive glial cells and its pathological implications. Biochim Biophys Acta 1834:2418-2428, 2013.
19. Gwak YS, Kang J, Unabia GC and Hulsebosch CE: Spatial and temporal activation of spinal glial cells: Role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol 234:362-372, 2012.
20. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF Jr, Spray DC, Reichenbach A, Pannicke T, et al: Glial cells in (patho) physiology. J Neurochem 121:4-27, 2012.
21. Watkins LR and Maier SF: Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 82:981-1011, 2002.
22. Barragán-Iglesias P, Pineda-Farias JB, Cervantes-Durán C, Bravo-Hernández M, Rocha-González HI, Murbartián J and Granados-Soto V: Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: Possible involvement of glial cells. Mol Pain 10:29, 2014.
23. Ji XT, Qian NS, Zhang T, Li JM, Li XK, Wang P, Zhao DS, Huang G, Zhang L, Fei Z, et al: Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapy-induced neuropathic pain model. PLoS One 8:e60733, 2013.
24. Chen FL, Dong YL, Zhang ZJ, Cao DL, Xu J, Hui J, Zhu L and Gao YJ: Activation of astrocytes in the anterior cingulate cortex contributes to the affective component of pain in an inflammatory pain model. Brain Res Bull 87:60-66, 2012.
25. Feng QX, Wang W, Feng XY, Mei XP, Zhu C, Liu ZC, Li YQ, Dou KF and Zhao QC: Astrocytic activation in thoracic spinal cord contributes to persistent pain in rat model of chronic pancreatitis. Neuroscience 167:501-509, 2010.
26. Cui J, He W, Yi B, Zhao H, Lu K, Ruan H and Ma D: mTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model. Neuroscience 275:395-403, 2014.
27. Shen W, Hu XM, Liu YN, Han Y, Chen LP, Wang CC and Song C: CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation 11:75, 2014.
28. Vega-Avelaira D, Ballesteros JJ and López-García JA: Inflammation-induced hyperalgesia and spinal microglia reactivity in neonatal rats. Eur J Pain 17:1180-1188, 2013.
29. Xu ZZ, Berta T and Ji RR: Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol 8:37-41, 2013.
30. Moss A, Beggs S, Vega-Avelaira D, Costigan M, Hathway GJ, Salter MW and Fitzgerald M: Spinal microglia and neuropathic pain in young rats. Pain 128:215-224, 2007.
31. Guo J, Jia D, Jin B, Xu F, Yuan X and Shen H: Effects of glial cell line-derived neurotrophic factor intrathecal injection on spinal dorsal horn glial fibrillary acidic protein expression in a rat model of neuropathic pain. Int J Neurosci 122:388-394, 2012.
32. Blum E, Procacci P, Conte V and Hanani M: Systemic inflammation alters satellite glial cell function and structure. A possible contribution to pain. Neuroscience 274:209-217, 2014.
33. Cao FL, Xu M, Wang Y, Gong KR and Zhang JT: Tanshinone IIA attenuates neuropathic pain via inhibiting glial activation and immune response. Pharmacol Biochem Behav 128:1-7, 2015.
34. Silva GD, Lopes PS, Fonoff ET and Pagano RL: The spinal anti-inflammatory mechanism of motor cortex stimulation: Cause of success and refractoriness in neuropathic pain? J Neuroinflammation 12:10, 2015.
35. Zhu MD, Zhao LX, Wang XT, Gao YJ and Zhang ZJ: Ligustilide inhibits microglia-mediated proinflammatory cytokines production and inflammatory pain. Brain Res Bull 109:54-60, 2014.
36. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB and Malcangio M: P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci 30:573-582, 2010.
37. Luo XY, Qu SL, Tang ZH, Zhang Y, Liu MH, Peng J, Tang H, Yu KL, Zhang C, Ren Z and Zhang ZS: SIRT1 in cardiovascular aging. Clin Chim Acta 437:106-114, 2014.
38. Herskovits AZ and Guarente L: SIRT1 in neurodevelopment and brain senescence. Neuron 81:471-483, 2014.
39. Leibiger IB and Berggren PO: Sirt1: A metabolic master switch that modulates lifespan. Nat Med 12:34-36, 2006.
40. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P and Sachchidanand: Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun 401:13-19, 2010.
41. He X, Ou P, Wu K, Huang C, Wang Y, Yu Z and Guo Q: Resveratrol attenuates morphine antinociceptive tolerance via SIRT1 regulation in the rat spinal cord. Neurosci Lett 566:55-60, 2014.
42. Yin Q, Lu FF, Zhao Y, Cheng MY, Fan Q, Cui J, Liu L, Cheng W and Yan CD: Resveratrol facilitates pain attenuation in a rat model of neuropathic pain through the activation of spinal Sirt1. Reg Anesth Pain Med 38:93-99, 2013.
43. Shao H, Xue Q, Zhang F, Luo Y, Zhu H, Zhang X, Zhang H, Ding W and Yu B: Spinal SIRT1 activation attenuates neuropathic pain in mice. PLoS One 9:e100938, 2014.
44. Winnik S, Stein S and Matter CM: SIRT1-an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 10:693-696, 2012.
45. Xie J, Zhang X and Zhang L: Negative regulation of inflammation by SIRT1. Pharmacol Res 67:60-67, 2013.
46. Joe IS, Jeong SG and Cho GW: Resveratrol-induced SIRT1 activation promotes neuronal differentiation of human bone marrow mesenchymal stem cells. Neurosci Lett 584:97-102, 2015.
47. Li L, Sun Q, Li Y, Yang Y, Yang Y, Chang T, Man M and Zheng L: Overexpression of SIRT1 Induced by resveratrol and inhibitor of MIR-204 suppresses activation and proliferation of microglia. J Mol Neurosci 56:858-867, 2015.
48. Sin TK, Tam BT, Yung BY, Yip SP, Chan LW, Wong CS, Ying M, Rudd JA and Siu PM: Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J Physiol 593:1887-1899. 2015.
49. Han Y, Jiang C, Tang J, Wang C, Wu P, Zhang G, Liu W, Jamangulova N, Wu X and Song X: Resveratrol reduces morphine tolerance by inhibiting microglial activation via AMPK signalling. Eur J Pain 18:1458-1470, 2014.
50. Zong Y, Sun L, Liu B, Deng YS, Zhan D, Chen YL, He Y, Liu J, Zhang ZJ, Sun J and Lu D: Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One 7:e44107, 2012.
51. Centeno-Baez C, Dallaire P and Marette A: Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol Endocrinol Metab 301:E922-E930, 2011.
52. Yang H, Zhang W, Pan H, Feldser HG, Lainez E, Miller C, Leung S, Zhong Z, Zhao H, Sweitzer S, et al: SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kappaB activity. PLoS One 7:e46364, 2012.
53. Park GJ, Kim YS, Kang KL, Bae SJ, Baek HS, Auh QS, Chun YH, Park BH and Kim EC: Effects of sirtuin 1 activation on nicotine and lipopolysaccharide-induced cytotoxicity and inflammatory cytokine production in human gingival fibroblasts. J Periodontal Res 48:483-492, 2013.